The direct to consumer microbiome analyzing testers analyze the diversity of the gut microbiome assesses the number of species present and their ability to synthesize vitamins and butyrate. This essential short-chain fatty acid helps maintain the integrity of your gut lining. The ratios of different bacteria in your gut can influence your level of protection from obesity, diabetes type II, Crohn's disease, ulcerative colitis, and coronary heart disease. The microbiome analyzers analyze the DNA of the gut of an individual and its genetic predisposition towards any disease in particular. It helps in improving the gut of the individual by providing necessary dietary recommendations that can balance the microbiome. These testers include probiotics and beneficial bacteria report, dietary fiber breakdown and butyrate synthesis, personalized food recommendations.
MARKET DYNAMICS
The direct to consumer microbiome analyzing market has shown a significant evolution over the forecast period. The market is driven by an increasing incidence of genetic disorders along with broad applications of direct to consumer microbiome analyzing in primary detection of oncology, chronic diseases, infections, and other genetic disorders that will propel the growth of the market during the forecast period. Many key manufacturers are majorly focusing on new product expansion and FDA approval. The growth in number of partnerships with academic research centers and alliances by key laboratories internationally will drive the growth of the market shortly. For instance, in June 2019, Atlas Biomed Group Limited (personalized health Technology Company) expanded its offerings for DNA and Microbiome tests in Canada, succeeding in solid success in the European market. However, less awareness related to the pipeline products in the DNA testing industry and less favorable outcomes along with fewer treatment options are few factors restraining the overall growth of the direct to consumer microbiome analyzing market on a global scale.
MARKET SCOPE
The "Direct to Consumer Microbiome Analyzing Market Analysis to 2028" is a specialized and in-depth study of the biotechnology in the healthcare industry with a particular focus on the global market trend analysis. This report provides an outline of the direct to consumer microbiome analyzing market with detailed market segmentation by product, application, and end-user. The direct to consumer microbiome analyzing market is expected to witness a high growth during the forecast period. The report elaborates on the vital statistics on the market status of the leading players in the direct to consumer microbiome analyzing the market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The direct to consumer microbiome analyzing market is segmented based on product, application, and end-user. Based on product, the market is segmented as gut microbiome testing kits, health sample kits, and other microbiome testing kits. Based on the application, the market is categorized as infections, gut conditions, metabolic disorders, cardiovascular diseases, and others. On the basis of end-user, the market is segmented as the hospitals, clinics, diagnostic centers, and others.
REGIONAL FRAMEWORK
The report provides a comprehensive outline of the industry, including both qualitative and quantitative information. It gives a sketch and forecast of the direct to consumer microbiome analyzing market based on various segments. It also comprises of market size and forecast estimates from the year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The direct to consumer microbiome analyzing market by each region is later sub-segmented into respective countries and segments. The report comprises of the analysis and forecast of 18 countries globally, along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the direct to consumer microbiome analyzing market from both the demand and supply side. Further, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also covers an accurate PEST analysis for all five regions, namely; North America, Europe, MEA, APAC, and South & Central America, after evaluating political, economic, social, and technological factors affecting the direct to consumer microbiome analyzing market in these regions.
MARKET PLAYERS
The report contains critical developments in the direct to consumer microbiome analyzing market as organic and inorganic growth strategies. Numerous firms are focusing on organic growth strategies like product approvals, product launches, and others, such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the direct to consumer microbiome analyzing market are anticipated to have profitable growth opportunities in the coming years with the rising demand for direct to consumer microbiome analyzing in the global market. Mentioned below is the list of few companies engaged in the direct to consumer microbiome analyzing market.
The report also contains the profiles of key players in the direct to consumer microbiome analyzing market, along with their SWOT analysis and market strategies. Moreover, the report focuses on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.
- Atlas Biomed Group Limited.
- Viome, Inc.
- 23andMe, Inc
- uBiome
- Carbiotix AB
- BIOMES NGS GmbH
- Quantbiome, Inc.
- TFTAK
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the current study.